ES475857A1 - Un metodo para la manufactura del polipeptido de secuencia r-x-lis-y-gln-r' - Google Patents

Un metodo para la manufactura del polipeptido de secuencia r-x-lis-y-gln-r'

Info

Publication number
ES475857A1
ES475857A1 ES475857A ES475857A ES475857A1 ES 475857 A1 ES475857 A1 ES 475857A1 ES 475857 A ES475857 A ES 475857A ES 475857 A ES475857 A ES 475857A ES 475857 A1 ES475857 A1 ES 475857A1
Authority
ES
Spain
Prior art keywords
polypeptides
seryl
methods
alamyl
asparagyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES475857A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/960,550 external-priority patent/US4232008A/en
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of ES475857A1 publication Critical patent/ES475857A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C07K7/062—Serum thymic factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen nuevos polipéptidos biológicamente activos que contienen el siguiente segmento polipéptido: ALA-LIS-SER-GLN Generalmente se mantiene la actividad biológica cuando se sustituye un resto aminoácido natural o no natural por L-alcalino en la primera posición y/o L-serilo en la tercer posición. Estos polipéptidos son capaces de inducir la diferenciación de T-linfocitos, medida por la adquisición del antígeno de diferenciación tímico Th-1, así como de B-linfocitos, medida por la adquisición del antígeno de diferenciación Bu-1, Por lo tanto, los polipéptidos son útiles en la función química y en las áreas de inmunidad, por ejemplo en el tratamiento de la ausencia congénita de timo. Asimismo , se proporcionan polipéptidos sustituidos, métodos de manufactura de los polipéptidos, composiciones terapéuticas y métodos para uso de los polipéptidos.
ES475857A 1977-12-08 1978-12-07 Un metodo para la manufactura del polipeptido de secuencia r-x-lis-y-gln-r' Expired ES475857A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85849677A 1977-12-08 1977-12-08
US94053178A 1978-09-08 1978-09-08
US05/960,550 US4232008A (en) 1978-11-17 1978-11-17 Tetrapeptides and methods

Publications (1)

Publication Number Publication Date
ES475857A1 true ES475857A1 (es) 1980-01-16

Family

ID=27420392

Family Applications (1)

Application Number Title Priority Date Filing Date
ES475857A Expired ES475857A1 (es) 1977-12-08 1978-12-07 Un metodo para la manufactura del polipeptido de secuencia r-x-lis-y-gln-r'

Country Status (19)

Country Link
JP (1) JPS5498719A (es)
CA (1) CA1120031A (es)
CH (1) CH642058A5 (es)
DE (1) DE2853002A1 (es)
DK (1) DK149595C (es)
ES (1) ES475857A1 (es)
FI (1) FI67368C (es)
FR (1) FR2411174A1 (es)
GB (1) GB2014581B (es)
GR (1) GR65013B (es)
IE (1) IE47611B1 (es)
IL (1) IL56150A (es)
IT (1) IT1110889B (es)
NL (1) NL7812004A (es)
NO (1) NO149631C (es)
NZ (1) NZ189101A (es)
PT (1) PT68883A (es)
SE (1) SE444687B (es)
YU (1) YU41322B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215112A (en) * 1979-03-14 1980-07-29 Ortho Pharmaceutical Corporation Tripeptides and methods
US4215111A (en) * 1979-03-14 1980-07-29 Ortho Pharmaceutical Corporation Peptides having ubiquitin-like activity
CA1156220A (en) * 1979-04-26 1983-11-01 George Heavner Method and composition for preparation of h-sar-lys-sar-gln-nh.sub.2
US4426324A (en) * 1979-09-28 1984-01-17 Hoffmann-La Roche Inc. Immunopotentiating peptides
JPS5711950A (en) 1980-06-25 1982-01-21 Kureha Chem Ind Co Ltd Peptide and its synthesis
FR2546164B1 (fr) * 1983-05-16 1987-07-17 Centre Nat Rech Scient Nouveaux derives de peptides, leur preparation et leur application comme inhibiteurs de l'elastase
FR2741076B1 (fr) * 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant
RU2210382C1 (ru) * 2002-07-09 2003-08-20 Терентьев Александр Александрович Пептид, обладающий иммунорегуляторным свойством, и его композиция

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2544348C3 (de) * 1975-10-03 1979-12-13 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen L-Leucin-13-Motilin, Verfahren zu dessen Herstellung und dasselbe enthaltendes Mittel
FR2391994A1 (fr) * 1977-05-25 1978-12-22 Anvar Nouveaux polypeptides a activite thymique ou a activite antagoniste et leurs procedes de synthese
IT1156766B (it) * 1977-05-25 1987-02-04 Anvar Polipeptidi dotati di attivita' timica o antagonista e procedimento per la loro sintesi
FR2423481A2 (fr) * 1978-04-21 1979-11-16 Anvar Nouveaux polypeptides a activite thymique ou a activite antagoniste et leurs procedes de synthese

Also Published As

Publication number Publication date
FI67368B (fi) 1984-11-30
YU288078A (en) 1983-02-28
IL56150A0 (en) 1979-03-12
SE7812614L (sv) 1979-06-09
CA1120031A (en) 1982-03-16
DE2853002A1 (de) 1979-06-13
PT68883A (en) 1979-01-01
NO784128L (no) 1979-06-11
YU41322B (en) 1987-02-28
FI783769A (fi) 1979-06-09
NO149631B (no) 1984-02-13
CH642058A5 (de) 1984-03-30
GR65013B (en) 1980-06-12
NO149631C (no) 1984-05-23
FR2411174A1 (fr) 1979-07-06
IE47611B1 (en) 1984-05-02
JPS6327360B2 (es) 1988-06-02
GB2014581B (en) 1982-05-19
FI67368C (fi) 1985-03-11
IE782423L (en) 1979-06-08
DK149595B (da) 1986-08-04
NL7812004A (nl) 1979-06-12
DK554078A (da) 1979-06-09
FR2411174B1 (es) 1984-05-25
IT7852239A0 (it) 1978-12-07
JPS5498719A (en) 1979-08-03
IT1110889B (it) 1986-01-06
IL56150A (en) 1982-02-28
GB2014581A (en) 1979-08-30
SE444687B (sv) 1986-04-28
DK149595C (da) 1987-03-23
NZ189101A (en) 1984-07-06

Similar Documents

Publication Publication Date Title
ATE92080T1 (de) Isolierung und strukturbestimmung des zytostatischen linearen depsipeptids dolastatin 15.
ZA943464B (en) Vascular endothelial growth factor 2
AU531556B2 (en) Tripeptides
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
ES475857A1 (es) Un metodo para la manufactura del polipeptido de secuencia r-x-lis-y-gln-r'
WO1993019178A3 (en) Peptides useful for inducing tolerance
DK0523330T3 (da) Implanterbare sammensætninger indeholdende et biologisk aktivt protein, peptid eller polypeptid
Blumenthal Structure and action of heteronemertine polypeptide toxins. Membrane penetration by Cerebratulus lacteus toxin A-III
Ciardelli et al. Activity of synthetic thymosin. alpha. 1 C-terminal peptides in the azathioprine E-rosette inhibition assay
Maeda et al. Improvement of Macrophage Dysfunction by Administration of Anti‐transforming Growth Factor‐β Antibody in EL4‐bearing Hosts
Chiarenza et al. Modulating effects of the synthetic thymic dipeptide pidotimod on the immune system in the aging rat
GB1536878A (en) Octapeptide
IL129855A (en) Immunotrophic Isolated Protein-Related Breastfeeding Protein (CD14), Its Uses, In vitro Method for Immersion in B Cell Tumor and Differentiation and Vaccine Preparation Kit
FR2408581A1 (fr) Composition de pentapeptide, son procede d'obtention et composition therapeutique en comportant
EP0361977A3 (en) Peptides having t cell suppressor activity
Devens et al. Antipeptide antibody specific for the N-terminal of soluble immune response suppressor neutralizes concanavalin A and IFN-induced suppressor cell activity in an in vitro cytotoxic T lymphocyte response.
RU2136308C1 (ru) Стимулятор роста костно-мозговых клеток человека
Gruner et al. Stimulation of the recruitment of epidermal Langerhans cells by splenopentin
Elouaer-Blanc et al. Bombesin (BBS) stimulation of gastrin release from gastrinoma cells in long term culture
Hattori et al. Autocrine stimulation of interleukin 1β in acute myelogenous leukemia cells
Abiko et al. Syntheses and Immunological Effects of Thymic Humoral Factor‐γ2 and Its Phe7‐Substituted Analogues
Sztein et al. Recent Advances in Thymic Hormone Research
Oldham Biologicals and other biological response modifiers: preclinical and clinical assessment in cancer treatment
FI883765A (fi) Antikroppar mot biologiskt aktiva polypeptider och deras anvaendning vid diagnostiska foerfaranden.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19980202